Sanofi India profit and loss

Latest FY26

Revenue: ₹1,837cr−8.7% on FY25
EBITDA: ₹491cr+0.1% on FY25
Net profit: ₹327cr−21.0% on FY25
EPS: ₹141.85−20.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Dec 2025	FY25Dec 2024	FY24Dec 2023	FY23Dec 2022	FY22 and earlierAlpha Plus

Expenses
	1,822	1,837	2,013	2,851	2,770	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	18.9	19.7	16.5	65.3	71.5
	1,840	1,857	2,030	2,916	2,842
	237	246	355	564	550
	659	514	564	929	651
	10.1	137	60.2	−292	−11.1
	172	185	240	371	406
	1.4	1.7	1.5	1.7	1.7
	36.2	37.3	36.7	39.6	41.9
	235	264	303	476	470
	1,350	1,385	1,561	2,088	2,109
	510	491	491	804	704
	473	454	454	764	663
Profit
	491	472	469	828	732
	0.0	−27.3	−37.7	17.8	132
	491	445	431	846	864
	126	123	126	243	245
	0.7	−4.9	−8.1	−0.7	−1.5
	126	118	118	243	244
	365	327	414	603	621
	365	327	314	603	621
	0.0	0.0	99.8	0.0	0.0
	1.7	1.7	7.2	−1.3	0.5
	366	328	421	602	621
Per share
	₹158.27	₹141.85	₹179.00	₹261.91	₹269.47
	₹158.27	₹141.85	₹179.00	₹261.91	₹269.47
Continuing & discontinued operations
	0.0	0.0	131	0.0	0.0
	0.0	0.0	31.4	0.0	0.0
Other comprehensive income — detail
	—	1.7	—	—	—
	—	2.3	—	−1.8	0.6
	—	0.6	—	—	—
	—	—	−9.6	−0.5	0.1
	—	—	2.4	—	—
Per share — as-filed variants
	₹158.27	₹141.85	₹136.00	₹261.91	₹269.47
	₹158.27	₹141.85	₹136.00	₹261.91	₹269.47
	₹0.00	₹0.00	₹43.00	₹0.00	₹0.00
	₹0.00	₹0.00	₹43.00	₹0.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	916	940	1,034	1,650	1,581
	50.3%	51.2%	51.4%	57.9%	57.1%
Adjusted (ex-exceptional items) — derived
	491	472	469	828	732
	0.0	−27.3	−37.7	17.8	132
	365	347	441	591	526
	₹158.27	₹150.56	₹190.87	₹256.40	₹228.32

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SANOFI₹2,992.00

Sanofi India Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSENORES INNOVACAP PGHL MOREPENLAB IOLCP SANOFICONR FDC ORCHPHARMAMcap ₹6,882 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/12/2022	FY24 31/12/2023	FY25 31/12/2024	FY26 31/12/2025	Last 12M 30/09/2026
Revenue from Operations	2,770.1	2,851.1	2,013.2	1,837.4	1,821.5
Other Income	71.5	65.3	16.5	19.7	18.9
Total Income	2,841.6	2,916.4	2,029.7	1,857.1	1,840.4
Expenses
+ Cost of Materials Consumed	549.7	564.4	354.8	246.4	236.5
+ Purchases of Stock-in-Trade	651.0	929.0	564.3	514.0	659.0
+ Changes in Inventories	-11.1	-292.4	60.2	136.8	10.1
+ Employee Benefit Expense	405.9	370.6	240.2	185.3	171.8
+ Finance Costs	1.7	1.7	1.5	1.7	1.4
+ Depreciation & Amortisation	41.9	39.6	36.7	37.3	36.2
+ Other Expenses	470.2	475.5	302.9	263.6	234.5
Total Expenses	2,109.3	2,088.4	1,560.6	1,385.1	1,349.5
EBITDA	704.4	804.0	490.8	491.3	509.6
EBIT	662.5	764.4	454.1	454.0	473.4
Profit
PBT before Exceptional Items	732.3	828.0	469.1	472.0	490.9
+ Exceptional Items	132.0	17.8	-37.7	-27.3	0.0
Pretax Income	864.3	845.8	431.4	444.7	490.9
+ Current Tax	245.2	243.3	125.8	122.9	125.7
+ Deferred Tax	-1.5	-0.7	-8.1	-4.9	0.7
Tax Expense	243.7	242.6	117.7	118.0	126.4
Net Income	620.6	603.2	413.5	326.7	364.5
+ Net Income — Continuing Ops	620.6	603.2	313.7	326.7	364.5
+ Net Income — Discontinued Ops	0.0	0.0	99.8	0.0	0.0
+ Other Comprehensive Income	0.5	-1.3	7.2	1.7	1.7
Total Comprehensive Income	621.1	601.9	420.7	328.4	366.2
Per Share
Basic EPS	269.47	261.91	179.00	141.85	158.27
Diluted EPS	269.47	261.91	179.00	141.85	158.27
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	131.2	0.0	0.0
+ Tax — Discontinued Operations	0.0	0.0	31.4	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	1.7	—
+ Items NOT to be Reclassified to P&L	0.6	-1.8	—	2.3	—
+ Tax on Items NOT to be Reclassified	—	—	—	0.6	—
+ Tax on Items NOT to be Reclassified — alt tag	0.1	-0.5	-9.6	—	—
+ Tax on Items to be Reclassified — alt tag	—	—	2.4	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	269.47	261.91	136.00	141.85	158.27
Diluted EPS — Continuing Operations	269.47	261.91	136.00	141.85	158.27
Basic EPS — Discontinued Operations	0.00	0.00	43.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	0.00	43.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,580.5	1,650.1	1,033.9	940.2	915.9
Gross Margin %	57.06	57.88	51.36	51.17	50.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	732.3	828.0	469.1	472.0	490.9
− Exceptional Items (reconciliation)	132.0	17.8	-37.7	-27.3	0.0
Net Income Adj (tax-effected)	525.8	590.5	440.9	346.8	364.5
EPS Adj	228.32	256.40	190.87	150.56	158.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	23.0	23.0	23.0	23.0	23.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.